Dynamed Clinical Research — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,800,744	467
2024	Research	$899,589	620
2023	Research	$488,531	310
2022	Research	$447,036	260
2021	Research	$75,074	14
2020	Research	$220,414	25
2019	Research	$379,900	17

Breakdown

Who paid Research payments · program years 2019–2025

Seqirus USA Inc $2,228,826 1,653 payments
AstraZeneca Pharmaceuticals LP $1,761,696 47 payments
AstraZeneca UK Limited $313,653 8 payments
AstraZeneca AB $3,800 1 payment
Pfizer Inc. $3,312 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $913,733 376 payments
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler $671,811 12 payments
The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $552,432 493 payments
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event $501,294 2 payments
A Phase 2b, Randomized, Observer-Blind, Antigen and Adjuvant Dose-Confirmation Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Cell-derived Influenza Vaccine (aQIVc) in Older Adults =50 Years of Age $365,392 679 payments
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $284,691 2 payments
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $188,486 4 payments
A Phase 3, Randomized, Observer-Blind, Multicenter, Noninferiority Study to Evaluate Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine QIVc and a United States Licensed Quadrivalent Influenza Virus Vaccine QIV in Healthy Subjects 6 Months Through 47 Months $142,031 6 payments
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event $135,755 4 payments
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults $122,191 16 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.